EPO is commonly marketed under the brand names Procrit® and Epogen® in the US, Eprex and NeoRecormon in Europe and elsewhere. Synthetic (recombinant) EPO is frequently prescribed to patients who are receiving kidney dialysis, since natural production is inhibited by both the disease and the dialysis.
In cases of blood loss resulting in severe anemia, that involve those who for religious reasons do not accept blood or blood products, Hospital Liaison Committee members (there are currently about 850 of these committees worldwide) are available with information and current medical literature for physicians, showing the efficacy of recombinant erythropoietin (EPO) in increased production of red blood cells. This synthetic hormone acts like the natural erythropoietin found in our kidneys and stimulates the bone marrow to send new, fresh red cells into the bloodstream.
While recombinant erythropoietin itself is not a blood product, some brands of the synthetic form do contain a very small amount of albumin, which is a minor blood fraction. Epogen® and Procrit® contain 2.5 mg human serum albumin, which prevents the drug from sticking to the vial, and acts as a carrier molecule to help the EPO remain in the bloodstream until it reaches its destination at the bone marrow.
Resources and Additional Reading:
Copyright © 2021 Allegheny Health Network. All rights reserved